AtriCure Shorts Ease, But Analyst Targets Jump Ahead of Earnings

ATRC enters its October 29 earnings report with short sellers pulling back even as the options market swings hard toward calls, a split that makes the positioning picture unusually difficult to read.

Short interest has climbed roughly 15% over the past month to 9.5% of free float, a meaningful level for a mid-cap medical device name. The week, however, told a different story: that position has barely moved, down less than 0.3% across the five sessions to 4.75 million shares. Borrow costs reinforce the sense that pressure has eased. The cost to borrow has fallen 16% week-on-week to 0.47%, its lowest point in a month. Availability is generous, with roughly 567% of current short interest still available in the lending pool, meaning there is no tightness in supply for anyone who wants to add or maintain a short position. The month-long build in the short book has not translated into any squeeze dynamic.

Options positioning tells a sharply different story. Investors are loading up on calls at an extreme pace: the put/call ratio has collapsed to 0.05, nearly three standard deviations below its 20-day average of 0.15. That is the most call-heavy reading relative to recent history in close to a year, suggesting options traders are positioned for upside into next week's print rather than hedging against a miss. The stock gained 1.4% over the past week, modestly behind the 2.3% median move for its closest peers, which included gains of 3.5% for STE and 3.5% for GMED.

The analyst community has moved constructively into the earnings. Citizens raised its target from $52 to $68 this week while keeping a Market Outperform rating. BTIG lifted its target from $55 to $63 earlier in October. The direction of travel across the past two months has been almost uniformly upward: Needham, Piper Sandler, and BTIG have all raised targets since August, and only Freedom Capital Markets broke ranks, downgrading to Hold while still raising its target to $57. The consensus mean price target now sits at roughly $57.56, very close to the current price of $57.67, which itself reflects how far the targets have chased the stock's 2026 rally rather than leading it. EPS momentum scores are among the strongest in the universe, ranking in the 98th percentile on a 90-day basis, and the company has a near-perfect EPS surprise record. The valuation multiple is less comfortable: the stock trades on a trailing P/E of around 143 times, and the EV/EBITDA sits near 29 times. The bull case rests on the STS quality measure for pre-operative atrial fibrillation and a potential positive BoxX-NoAF readout in the first half of 2027, which together could materially expand AtriCure's addressable market. The bear case centres on the deferral of those catalysts to 2028 at the earliest, against a base of $535 million in 2025 revenue and adjusted EBITDA of only $62 million.

Insider activity over the past 90 days has been one-way. Net sales of roughly 74,900 shares totalling $3.3 million have been filed since late July, spread across the Chief Technical Officer, Chief Legal Officer, Chief Marketing and Strategy Officer, and multiple directors. A portion of the CTO's sales were under a pre-arranged 10b5-1 plan, which reduces their signal value, but the director sales were discretionary. No insider has filed a purchase over this period. BlackRock filed an amended 13G in early October showing a stake of 15.4%, roughly double its previously disclosed 7.8% holding, a notable change in reported position size for the company's largest institution, though the stake remains passive and the disclosure note applies: holdings are as last filed and may not reflect the current position.

The prior two earnings prints produced single-day moves of roughly 9% and 4.5% respectively, with the five-day windows extending to 4% and 20%. The widest post-earnings swing over that window came after the July 23 report. With the short book elevated but static, borrowing conditions easy, and options skewed heavily toward calls, what matters next is whether the Q3 revenue print and any update on the BoxX-NoAF timeline justify the call premium the market is currently paying.